BridgeMD
Usefulness of Corifollitropin alfa as alternative to conventional daily rFSH protocols in oocyte donors undergoing pituitary suppression with Medroxiprogesterona acetate (MPA).
EU CTIS ID: 2023-506908-66-00
What this study is testing
To compare the number of total oocytes and metaphase II (MII) oocytes obtained after controlled ovarian stimulation with α-Corifolitropin vs. β-Folitropin in donors in whom medroxyprogesterone acetate (MPA) has been used to prevent early luteinisation.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Signature of subject's informed consent prior to any trial-related activity. - Age between 18 and 35 years (inclusive). - Regular menstrual cycle, 25 to 35 days (both inclusive). - Absence of physical and mental illness at the time of donation at the discretion of the investigator. - BMI 18-28 kg/m2 (both inclusive) at the time of donation. - No personal or family history of interest at the discretion of the investigator. - Normal uterus and ovaries, without organic pathology. - No polycystic ovaries. - Antral follicle count greater than 12 in the sum of the two ovaries at the time of the selection visit. - Normal karyotype. - Negative screening for infectious diseases (Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus and Syphilis). - General analysis with haemogram, haemostasis and biochemistry with parameters within normality.
You likely can't join if
- - Concurrent participation in another clinical trial. - Previous participation in this clinical trial. - Any systemic or metabolic disorder (i.e.: diabetes...) that contraindicates the use of gonadotrophins. - Personal history of thrombophlebitis and thromboembolic phenomena and AHT. - Severe hepatic insufficiency, cardiovascular disease. - Suspicion or evidence of breast or hormone-dependent genital organ malignancy - known hypersensitivity to MPA or its excipients - Use of long-term hormonal contraception (hormonal IUDs or subcutaneous implants) at least 1 month prior to inclusion - Any reason for exclusion from the oocyte donation programme
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.